Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7474327,T 1/2 beta,"Average T 1/2 beta of SPFX was 25.7 hours, and it was prolonged compared to the patients with renal failure (who were not receiving hemodialysis) and a group of young healthy volunteers.",[Pharmacokinetic study of sparfloxacin in patients receiving regular hemodialysis]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7474327/),h,25.7,2348,DB01208,Sparfloxacin
,9559797,MIC,"Trovafloxacin is a novel naphthyridone quinolone with promising activity against S. pneumoniae, including penicillin-resistant strains (MIC for 90% of the isolates tested, 0.25 microg/ml).",Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559797/),[μg] / [ml],0.25,6718,DB01208,Sparfloxacin
,9559797,MIC,"Immunocompetent Swiss mice were infected by peroral tracheal delivery of a virulent, penicillin-susceptible strain (MIC, 0.03 microg/ml); leukopenic Swiss mice were infected with three poorly virulent, penicillin-resistant strains (MICs, 4 to 8 microg/ml) and a ciprofloxacin-resistant strain (MIC, 32 microg/ml).",Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559797/),[μg] / [ml],0.03,6719,DB01208,Sparfloxacin
,9559797,MICs,"Immunocompetent Swiss mice were infected by peroral tracheal delivery of a virulent, penicillin-susceptible strain (MIC, 0.03 microg/ml); leukopenic Swiss mice were infected with three poorly virulent, penicillin-resistant strains (MICs, 4 to 8 microg/ml) and a ciprofloxacin-resistant strain (MIC, 32 microg/ml).",Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559797/),[μg] / [ml],4 to 8,6720,DB01208,Sparfloxacin
,9559797,MIC,"Immunocompetent Swiss mice were infected by peroral tracheal delivery of a virulent, penicillin-susceptible strain (MIC, 0.03 microg/ml); leukopenic Swiss mice were infected with three poorly virulent, penicillin-resistant strains (MICs, 4 to 8 microg/ml) and a ciprofloxacin-resistant strain (MIC, 32 microg/ml).",Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559797/),[μg] / [ml],32,6721,DB01208,Sparfloxacin
,8388193,maximum concentration,"After systemic administration to rabbits, the maximum concentration of sparfloxacin in serum was 5.6 micrograms.",Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388193/),μg,5.6,6938,DB01208,Sparfloxacin
,8388193,half-life,ml-1 and the half-life was 7.5 h.,Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388193/),h,7.5,6939,DB01208,Sparfloxacin
,8388193,penetration ratios,"Sparfloxacin exhibited very good penetration ratios in the vitreous (54%), cornea (76%), and lens (36%).",Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388193/),%,54,6940,DB01208,Sparfloxacin
,8388193,penetration ratios,"Sparfloxacin exhibited very good penetration ratios in the vitreous (54%), cornea (76%), and lens (36%).",Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388193/),%,76,6941,DB01208,Sparfloxacin
,8388193,penetration ratios,"Sparfloxacin exhibited very good penetration ratios in the vitreous (54%), cornea (76%), and lens (36%).",Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388193/),%,36,6942,DB01208,Sparfloxacin
,8851610,inhibitory titers,Geometric mean inhibitory titers ranged between 1:2.4 and 1:6.3 and bactericidal titers ranged between 1:1.3 and 1:3.6 during a time period of 1 to 6 h after drug intake.,Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851610/),,1,14615,DB01208,Sparfloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],1.2,39031,DB01208,Sparfloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],1.71,39032,DB01208,Sparfloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],2.17,39033,DB01208,Sparfloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],2.48,39034,DB01208,Sparfloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],4.6,39035,DB01208,Sparfloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],15,39036,DB01208,Sparfloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],17.9,39037,DB01208,Sparfloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],19.7,39038,DB01208,Sparfloxacin
,10440622,time to Cmax,"As indicated by an increase in the time to Cmax from 3.6 to 5.4 hours, the high-fat breakfast slightly delayed the onset of sparfloxacin absorption.",Effects of food on the pharmacokinetics of sparfloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440622/),h,3.6,41579,DB01208,Sparfloxacin
,10440622,time to Cmax,"As indicated by an increase in the time to Cmax from 3.6 to 5.4 hours, the high-fat breakfast slightly delayed the onset of sparfloxacin absorption.",Effects of food on the pharmacokinetics of sparfloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440622/),h,5.4,41580,DB01208,Sparfloxacin
,7876398,Cmax,"Mean Cmax values ranged from 705 +/- 158 to 1966 +/- 620 ng/mL for the 200 to 800 mg doses, at median tmax ranging from 4 to 5 hours.","Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7876398/),[ng] / [ml],705,42158,DB01208,Sparfloxacin
,7876398,Cmax,"Mean Cmax values ranged from 705 +/- 158 to 1966 +/- 620 ng/mL for the 200 to 800 mg doses, at median tmax ranging from 4 to 5 hours.","Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7876398/),[ng] / [ml],1966,42159,DB01208,Sparfloxacin
,7876398,tmax,"Mean Cmax values ranged from 705 +/- 158 to 1966 +/- 620 ng/mL for the 200 to 800 mg doses, at median tmax ranging from 4 to 5 hours.","Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7876398/),h,4 to 5,42160,DB01208,Sparfloxacin
,7876398,elimination half-life,The elimination half-life values were constant over the dose range (with values ranging from 18 to 21 hours) as well as the renal clearance.,"Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7876398/),h,18 to 21,42161,DB01208,Sparfloxacin
,11389113,Maximum kills,Maximum kills ranged from 5 to >6 logs.,"Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389113/),logs,5 to >6,42722,DB01208,Sparfloxacin
,8031039,MICs,"The MICs of sparfloxacin, erythromycin, levofloxacin, ofloxacin, and minocycline for 90% of the 43 M. pneumoniae strains tested were 0.063, 0.016, 0.5, 1, and 0.5 microgram/ml, respectively.",In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031039/),[μg] / [ml],0.063,43941,DB01208,Sparfloxacin
,8031039,MICs,"The MICs of sparfloxacin, erythromycin, levofloxacin, ofloxacin, and minocycline for 90% of the 43 M. pneumoniae strains tested were 0.063, 0.016, 0.5, 1, and 0.5 microgram/ml, respectively.",In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031039/),[μg] / [ml],0.016,43942,DB01208,Sparfloxacin
,8031039,MICs,"The MICs of sparfloxacin, erythromycin, levofloxacin, ofloxacin, and minocycline for 90% of the 43 M. pneumoniae strains tested were 0.063, 0.016, 0.5, 1, and 0.5 microgram/ml, respectively.",In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031039/),[μg] / [ml],0.5,43943,DB01208,Sparfloxacin
,8031039,MICs,"The MICs of sparfloxacin, erythromycin, levofloxacin, ofloxacin, and minocycline for 90% of the 43 M. pneumoniae strains tested were 0.063, 0.016, 0.5, 1, and 0.5 microgram/ml, respectively.",In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031039/),[μg] / [ml],1,43944,DB01208,Sparfloxacin
,2327763,peak levels,"The mean peak levels of AT-4140 in plasma of mice, rats, dogs, and monkeys were 0.25, 0.50, 1.14, and 0.49 micrograms/ml, respectively, with mean elimination half-lives of 5.0, 3.8, 8.0, and 11.7 h, respectively.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),[μg] / [ml],0.25,48765,DB01208,Sparfloxacin
,2327763,peak levels,"The mean peak levels of AT-4140 in plasma of mice, rats, dogs, and monkeys were 0.25, 0.50, 1.14, and 0.49 micrograms/ml, respectively, with mean elimination half-lives of 5.0, 3.8, 8.0, and 11.7 h, respectively.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),[μg] / [ml],0.50,48766,DB01208,Sparfloxacin
,2327763,peak levels,"The mean peak levels of AT-4140 in plasma of mice, rats, dogs, and monkeys were 0.25, 0.50, 1.14, and 0.49 micrograms/ml, respectively, with mean elimination half-lives of 5.0, 3.8, 8.0, and 11.7 h, respectively.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),[μg] / [ml],1.14,48767,DB01208,Sparfloxacin
,2327763,peak levels,"The mean peak levels of AT-4140 in plasma of mice, rats, dogs, and monkeys were 0.25, 0.50, 1.14, and 0.49 micrograms/ml, respectively, with mean elimination half-lives of 5.0, 3.8, 8.0, and 11.7 h, respectively.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),[μg] / [ml],0.49,48768,DB01208,Sparfloxacin
,2327763,elimination half-lives,"The mean peak levels of AT-4140 in plasma of mice, rats, dogs, and monkeys were 0.25, 0.50, 1.14, and 0.49 micrograms/ml, respectively, with mean elimination half-lives of 5.0, 3.8, 8.0, and 11.7 h, respectively.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),h,5.0,48769,DB01208,Sparfloxacin
,2327763,elimination half-lives,"The mean peak levels of AT-4140 in plasma of mice, rats, dogs, and monkeys were 0.25, 0.50, 1.14, and 0.49 micrograms/ml, respectively, with mean elimination half-lives of 5.0, 3.8, 8.0, and 11.7 h, respectively.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),h,3.8,48770,DB01208,Sparfloxacin
,2327763,elimination half-lives,"The mean peak levels of AT-4140 in plasma of mice, rats, dogs, and monkeys were 0.25, 0.50, 1.14, and 0.49 micrograms/ml, respectively, with mean elimination half-lives of 5.0, 3.8, 8.0, and 11.7 h, respectively.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),h,8.0,48771,DB01208,Sparfloxacin
,2327763,elimination half-lives,"The mean peak levels of AT-4140 in plasma of mice, rats, dogs, and monkeys were 0.25, 0.50, 1.14, and 0.49 micrograms/ml, respectively, with mean elimination half-lives of 5.0, 3.8, 8.0, and 11.7 h, respectively.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),h,11.7,48772,DB01208,Sparfloxacin
,2327763,oral bioavailability,The oral bioavailability of AT-4140 calculated from the ratio of the areas under the concentration-time curve after oral and intravenous administration was 77% in dogs.,"Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,77,48773,DB01208,Sparfloxacin
,2327763,biliary recovery,The mean 24-h biliary recovery of AT-4140 in rats was 5.6% of the dose and became 21.3% after beta-glucuronidase treatment.,"Pharmacokinetics of a novel quinolone, AT-4140, in animals. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),,5,48774,DB01208,Sparfloxacin
,2327763,biliary recovery,The mean 24-h biliary recovery of AT-4140 in rats was 5.6% of the dose and became 21.3% after beta-glucuronidase treatment.,"Pharmacokinetics of a novel quinolone, AT-4140, in animals. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,21.3,48775,DB01208,Sparfloxacin
,2327763,urinary recoveries,"The mean 48-h urinary recoveries of AT-4140 in mice, rats, dogs, and monkeys were 6.7, 12.9, 8.6, and 12.7%, respectively, of the dose and were 7.8, 16.3, 8.9, and 18.9%, respectively, after beta-glucuronidase treatment.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,6.7,48776,DB01208,Sparfloxacin
,2327763,urinary recoveries,"The mean 48-h urinary recoveries of AT-4140 in mice, rats, dogs, and monkeys were 6.7, 12.9, 8.6, and 12.7%, respectively, of the dose and were 7.8, 16.3, 8.9, and 18.9%, respectively, after beta-glucuronidase treatment.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,12.9,48777,DB01208,Sparfloxacin
,2327763,urinary recoveries,"The mean 48-h urinary recoveries of AT-4140 in mice, rats, dogs, and monkeys were 6.7, 12.9, 8.6, and 12.7%, respectively, of the dose and were 7.8, 16.3, 8.9, and 18.9%, respectively, after beta-glucuronidase treatment.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,8.6,48778,DB01208,Sparfloxacin
,2327763,urinary recoveries,"The mean 48-h urinary recoveries of AT-4140 in mice, rats, dogs, and monkeys were 6.7, 12.9, 8.6, and 12.7%, respectively, of the dose and were 7.8, 16.3, 8.9, and 18.9%, respectively, after beta-glucuronidase treatment.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,12.7,48779,DB01208,Sparfloxacin
,2327763,urinary recoveries,"The mean 48-h urinary recoveries of AT-4140 in mice, rats, dogs, and monkeys were 6.7, 12.9, 8.6, and 12.7%, respectively, of the dose and were 7.8, 16.3, 8.9, and 18.9%, respectively, after beta-glucuronidase treatment.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,7.8,48780,DB01208,Sparfloxacin
,2327763,urinary recoveries,"The mean 48-h urinary recoveries of AT-4140 in mice, rats, dogs, and monkeys were 6.7, 12.9, 8.6, and 12.7%, respectively, of the dose and were 7.8, 16.3, 8.9, and 18.9%, respectively, after beta-glucuronidase treatment.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,16.3,48781,DB01208,Sparfloxacin
,2327763,urinary recoveries,"The mean 48-h urinary recoveries of AT-4140 in mice, rats, dogs, and monkeys were 6.7, 12.9, 8.6, and 12.7%, respectively, of the dose and were 7.8, 16.3, 8.9, and 18.9%, respectively, after beta-glucuronidase treatment.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,8.9,48782,DB01208,Sparfloxacin
,2327763,urinary recoveries,"The mean 48-h urinary recoveries of AT-4140 in mice, rats, dogs, and monkeys were 6.7, 12.9, 8.6, and 12.7%, respectively, of the dose and were 7.8, 16.3, 8.9, and 18.9%, respectively, after beta-glucuronidase treatment.","Pharmacokinetics of a novel quinolone, AT-4140, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327763/),%,18.9,48783,DB01208,Sparfloxacin
,16137962,peak level,"Fifteen minutes after the instillation of 50 microl of sparfloxacin 0.3% solution, the mean concentration in aqueous humour was found to be 1.4 microg/ml, which reaches the peak level of 3.7 microg/ml after 1.3 hours.",Pharmacokinetics of topically applied sparfloxacin in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16137962/),[μg] / [ml],3.7,55243,DB01208,Sparfloxacin
>,9687379,MICs,"The MICs at which 50% and 90% of bacteria were inhibited were >/=128 and >/=128 mg/liter, respectively, for ciprofloxacin, 16 and 32 mg/liter, respectively, for sparfloxacin, and 0.25 and 1 mg/liter, respectively, for Y-688.","Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687379/),[mg] / [l],128,62027,DB01208,Sparfloxacin
,9687379,MICs,"The MICs at which 50% and 90% of bacteria were inhibited were >/=128 and >/=128 mg/liter, respectively, for ciprofloxacin, 16 and 32 mg/liter, respectively, for sparfloxacin, and 0.25 and 1 mg/liter, respectively, for Y-688.","Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687379/),[mg] / [l],16,62028,DB01208,Sparfloxacin
,9687379,MICs,"The MICs at which 50% and 90% of bacteria were inhibited were >/=128 and >/=128 mg/liter, respectively, for ciprofloxacin, 16 and 32 mg/liter, respectively, for sparfloxacin, and 0.25 and 1 mg/liter, respectively, for Y-688.","Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687379/),[mg] / [l],32,62029,DB01208,Sparfloxacin
,9687379,MICs,"The MICs at which 50% and 90% of bacteria were inhibited were >/=128 and >/=128 mg/liter, respectively, for ciprofloxacin, 16 and 32 mg/liter, respectively, for sparfloxacin, and 0.25 and 1 mg/liter, respectively, for Y-688.","Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687379/),[mg] / [l],0.25,62030,DB01208,Sparfloxacin
,9687379,MICs,"The MICs at which 50% and 90% of bacteria were inhibited were >/=128 and >/=128 mg/liter, respectively, for ciprofloxacin, 16 and 32 mg/liter, respectively, for sparfloxacin, and 0.25 and 1 mg/liter, respectively, for Y-688.","Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687379/),[mg] / [l],1,62031,DB01208,Sparfloxacin
,9687379,peak,"The anticipated peak and trough levels of Y-688 were 4 and 1 mg/liter at 0.5 and 12 h, respectively.","Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687379/),[mg] / [l],4,62032,DB01208,Sparfloxacin
,9687379,trough levels,"The anticipated peak and trough levels of Y-688 were 4 and 1 mg/liter at 0.5 and 12 h, respectively.","Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687379/),[mg] / [l],1,62033,DB01208,Sparfloxacin
,10463515,time to C,"At steady state, the time to C ranged from 2.5 to 3.9 hours across all doses and days studied.",The cardiac pharmacodynamics of therapeutic doses of sparfloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463515/),h,2.5 to 3.9,91603,DB01208,Sparfloxacin
,10463515,half-life,The half-life ranged from 18.7 to 20.3 hours.,The cardiac pharmacodynamics of therapeutic doses of sparfloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463515/),h,18.7 to 20.3,91604,DB01208,Sparfloxacin
,2073101,MICs,All three antimicrobial agents had roughly equivalent activities when buffered charcoal yeast extract agar medium supplemented with 0.1% alpha-ketoglutarate was used as the test medium; the MICs for 90% of strains were 1.0 micrograms/ml for erythromycin and sparfloxacin and 0.5 microgram/ml for ciprofloxacin.,"In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073101/),[μg] / [ml],1.0,100100,DB01208,Sparfloxacin
,2073101,MICs,All three antimicrobial agents had roughly equivalent activities when buffered charcoal yeast extract agar medium supplemented with 0.1% alpha-ketoglutarate was used as the test medium; the MICs for 90% of strains were 1.0 micrograms/ml for erythromycin and sparfloxacin and 0.5 microgram/ml for ciprofloxacin.,"In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073101/),[μg] / [ml],0.5,100101,DB01208,Sparfloxacin
less,2073101,MICs,"Broth macrodilution MICs for two L. pneumophila strains in buffered yeast extract supplemented with 0.1% alpha-ketoglutarate were less than or equal to 0.03 microgram/ml for sparfloxacin, 0.06 microgram/ml for ciprofloxacin, and 0.25 microgram/ml for erythromycin; only erythromycin was inhibited by this medium.","In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073101/),[μg] / [ml],0.03,100102,DB01208,Sparfloxacin
,2073101,MICs,"Broth macrodilution MICs for two L. pneumophila strains in buffered yeast extract supplemented with 0.1% alpha-ketoglutarate were less than or equal to 0.03 microgram/ml for sparfloxacin, 0.06 microgram/ml for ciprofloxacin, and 0.25 microgram/ml for erythromycin; only erythromycin was inhibited by this medium.","In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073101/),[μg] / [ml],0.06,100103,DB01208,Sparfloxacin
,2073101,MICs,"Broth macrodilution MICs for two L. pneumophila strains in buffered yeast extract supplemented with 0.1% alpha-ketoglutarate were less than or equal to 0.03 microgram/ml for sparfloxacin, 0.06 microgram/ml for ciprofloxacin, and 0.25 microgram/ml for erythromycin; only erythromycin was inhibited by this medium.","In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073101/),[μg] / [ml],0.25,100104,DB01208,Sparfloxacin
,2073101,peak levels,"For the pharmacokinetic study, sparfloxacin was given (10 mg/kg of body weight) to infected guinea pigs by the intraperitoneal route; peak levels in serum and lung were 2.6 micrograms/ml and 1.6 micrograms/g, respectively, at 1 h, with a terminal-phase half-life of elimination from serum of 5 h.","In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073101/),[μg] / [ml],2.6,100105,DB01208,Sparfloxacin
,2073101,peak levels,"For the pharmacokinetic study, sparfloxacin was given (10 mg/kg of body weight) to infected guinea pigs by the intraperitoneal route; peak levels in serum and lung were 2.6 micrograms/ml and 1.6 micrograms/g, respectively, at 1 h, with a terminal-phase half-life of elimination from serum of 5 h.","In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073101/),[μg] / [g],1.6,100106,DB01208,Sparfloxacin
,2073101,terminal-phase half-life of elimination from serum,"For the pharmacokinetic study, sparfloxacin was given (10 mg/kg of body weight) to infected guinea pigs by the intraperitoneal route; peak levels in serum and lung were 2.6 micrograms/ml and 1.6 micrograms/g, respectively, at 1 h, with a terminal-phase half-life of elimination from serum of 5 h.","In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073101/),h,5,100107,DB01208,Sparfloxacin
,9655838,MIC,The lower MIC of SPFX compared with CPFX (0.25 vs. 0.75 microgram/ml) and its higher AUC/dose ratio (resulting from a lower serum peak but a longer half-life) translated into a greater area under the bactericidal curve.,Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9655838/),[μg] / [ml],0.25,106647,DB01208,Sparfloxacin
,9655838,MIC,The lower MIC of SPFX compared with CPFX (0.25 vs. 0.75 microgram/ml) and its higher AUC/dose ratio (resulting from a lower serum peak but a longer half-life) translated into a greater area under the bactericidal curve.,Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9655838/),[μg] / [ml],0.75,106648,DB01208,Sparfloxacin
greater,9655838,AUC/MIC ratio,"When the AUC/MIC ratio was greater than 160, the probability of a clinical cure was 100%, independently of the dosage schedule.",Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9655838/),,160,106649,DB01208,Sparfloxacin
,9777602,recovery,The recovery study of authentic analytes added to plasma at 0.1 to 0.8 microgram ml-1 was 94.9 +/- 0.98% and the lowest amount of sparfloxacin that could be detected was 50 ng ml-1 plasma.,High performance thin-layer chromatographic method for the determination of sparfloxacin in human plasma and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9777602/),%,94.9,109819,DB01208,Sparfloxacin
,1312292,PF/serum ratio,"The SPFX concentrations in prostatic fluid (PF) were 0.33 to 0.49 microgram/ml at 1 to 3 hours after oral administration of 200 mg, the PF/serum ratio being 1.15 to 1.47.",[Clinical and bacteriological study of sparfloxacin on bacterial prostatitis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1312292/),,1,114875,DB01208,Sparfloxacin
,1312292,bacterial eradication rate,"The bacterial eradication rate was 93.3% (14/15 strains), and eradication was complete in all 7 cases infected with gram-negative rods.",[Clinical and bacteriological study of sparfloxacin on bacterial prostatitis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1312292/),%,93.3,114876,DB01208,Sparfloxacin
,14613952,MIC,"The olamufloxacin MIC at which 50% of isolates are inhibited (MIC50) for 81 different Legionella spp. strains (59 type strains and 22 clinical isolates) was 0.008 mg/L, which was identical to sparfloxacin, whereas the MIC50s for erythromycin, levofloxacin and ciprofloxacin were 0.25, 0.032 and 0.032 mg/L, respectively.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),[mg] / [l],0.008,123820,DB01208,Sparfloxacin
,14613952,MIC50s,"The olamufloxacin MIC at which 50% of isolates are inhibited (MIC50) for 81 different Legionella spp. strains (59 type strains and 22 clinical isolates) was 0.008 mg/L, which was identical to sparfloxacin, whereas the MIC50s for erythromycin, levofloxacin and ciprofloxacin were 0.25, 0.032 and 0.032 mg/L, respectively.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),[mg] / [l],0.25,123821,DB01208,Sparfloxacin
,14613952,MIC50s,"The olamufloxacin MIC at which 50% of isolates are inhibited (MIC50) for 81 different Legionella spp. strains (59 type strains and 22 clinical isolates) was 0.008 mg/L, which was identical to sparfloxacin, whereas the MIC50s for erythromycin, levofloxacin and ciprofloxacin were 0.25, 0.032 and 0.032 mg/L, respectively.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),[mg] / [l],0.032,123822,DB01208,Sparfloxacin
,14613952,peak levels,"When olamufloxacin was given to the infected guinea pigs orally (5 mg/kg of body weight), peak levels in the lung were 3.02 mg/kg at 2 h post-administration, with a half-life of 3.41 h and an AUC0-12 of 12.31 mg.h/kg.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),[mg] / [kg],3.02,123823,DB01208,Sparfloxacin
,14613952,half-life,"When olamufloxacin was given to the infected guinea pigs orally (5 mg/kg of body weight), peak levels in the lung were 3.02 mg/kg at 2 h post-administration, with a half-life of 3.41 h and an AUC0-12 of 12.31 mg.h/kg.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),h,3.41,123824,DB01208,Sparfloxacin
,14613952,AUC0-12,"When olamufloxacin was given to the infected guinea pigs orally (5 mg/kg of body weight), peak levels in the lung were 3.02 mg/kg at 2 h post-administration, with a half-life of 3.41 h and an AUC0-12 of 12.31 mg.h/kg.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),[h·mg] / [kg],12.31,123825,DB01208,Sparfloxacin
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],0.12,126769,DB01208,Sparfloxacin
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],2.0,126770,DB01208,Sparfloxacin
,1663354,Cmax,Plasma level of radioactivity reached Cmax of 1.32 micrograms eq/ml within 1 h after oral administration and decreased with a half-life of about 4 h.,Disposition and metabolism of [14C]sparfloxacin in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663354/),[eq·μg] / [ml],1.32,128079,DB01208,Sparfloxacin
,1663354,half-life,Plasma level of radioactivity reached Cmax of 1.32 micrograms eq/ml within 1 h after oral administration and decreased with a half-life of about 4 h.,Disposition and metabolism of [14C]sparfloxacin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663354/),h,4,128080,DB01208,Sparfloxacin
,1336947,peak concentration,The mean peak concentration in plasma of 1.6 micrograms/ml was attained at a mean time of 2.7 h postdose.,Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336947/),[μg] / [ml],1.6,144420,DB01208,Sparfloxacin
,1336947,mean time,The mean peak concentration in plasma of 1.6 micrograms/ml was attained at a mean time of 2.7 h postdose.,Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336947/),h,2.7,144421,DB01208,Sparfloxacin
,1336947,peak concentration in inflammatory fluid,The mean peak concentration in inflammatory fluid of 1.3 micrograms/ml was attained at a mean time of 5 h postdose.,Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336947/),[μg] / [ml],1.3,144422,DB01208,Sparfloxacin
,1336947,elimination half-life,"The mean elimination half-life in plasma was 17.6 h, and that in inflammatory fluid was 19.7 h.",Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336947/),h,17.6,144423,DB01208,Sparfloxacin
,1336947,elimination half-life,"The mean elimination half-life in plasma was 17.6 h, and that in inflammatory fluid was 19.7 h.",Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336947/),h,19.7,144424,DB01208,Sparfloxacin
,1336947,overall penetration into inflammatory fluid,The overall penetration into inflammatory fluid was 117%.,Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336947/),%,117,144425,DB01208,Sparfloxacin
,8287631,peak (Cmax),Plasma sparfloxacin concentrations reach a peak (Cmax) of approximately 0.7 mg/L at 3 to 5 hours after a 200mg oral dose.,Clinical pharmacokinetics of sparfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287631/),[mg] / [l],0.7,152908,DB01208,Sparfloxacin
,8287631,elimination half-life (t1/2),"This is followed by a monophasic slow decrease, with an elimination half-life (t1/2) of 15 to 20 hours.",Clinical pharmacokinetics of sparfloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287631/),h,15 to 20,152909,DB01208,Sparfloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],14,155385,DB01208,Sparfloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],22,155386,DB01208,Sparfloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],21,155387,DB01208,Sparfloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],20,155388,DB01208,Sparfloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],47,155389,DB01208,Sparfloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],35,155390,DB01208,Sparfloxacin
up,8092837,peak concentrations,Kinetic modeling suggested that peak sparfloxacin concentrations in brain tissue may have occurred later than 3 to 5 h and that actual peak concentrations may therefore have been higher (up to 10 micrograms/g of tissue).,Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092837/),,10,155832,DB01208,Sparfloxacin
,8092837,50% inhibitory concentration (IC50),"The 50% inhibitory concentration (IC50) of ciprofloxacin was 250 microM (95.25 micrograms/ml), but in the presence of biphenyl acetic acid (BPAA), the IC50 of ciprofloxacin was only 0.6 microM (0.23 microgram/ml).",Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092837/),μM,250,155833,DB01208,Sparfloxacin
,8092837,50% inhibitory concentration (IC50),"The 50% inhibitory concentration (IC50) of ciprofloxacin was 250 microM (95.25 micrograms/ml), but in the presence of biphenyl acetic acid (BPAA), the IC50 of ciprofloxacin was only 0.6 microM (0.23 microgram/ml).",Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092837/),[μg] / [ml],95.25,155834,DB01208,Sparfloxacin
,8092837,IC50,"The 50% inhibitory concentration (IC50) of ciprofloxacin was 250 microM (95.25 micrograms/ml), but in the presence of biphenyl acetic acid (BPAA), the IC50 of ciprofloxacin was only 0.6 microM (0.23 microgram/ml).",Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092837/),μM,0.6,155835,DB01208,Sparfloxacin
,8092837,IC50,"The 50% inhibitory concentration (IC50) of ciprofloxacin was 250 microM (95.25 micrograms/ml), but in the presence of biphenyl acetic acid (BPAA), the IC50 of ciprofloxacin was only 0.6 microM (0.23 microgram/ml).",Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092837/),[μg] / [ml],0.23,155836,DB01208,Sparfloxacin
>,8092837,IC50,"In contrast, the IC50 of sparfloxacin alone or in the presence of BPAA was > 300 microM (> 100 micrograms/ml).",Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092837/),μM,300,155837,DB01208,Sparfloxacin
>,8092837,IC50,"In contrast, the IC50 of sparfloxacin alone or in the presence of BPAA was > 300 microM (> 100 micrograms/ml).",Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092837/),[μg] / [ml],100,155838,DB01208,Sparfloxacin
,8031038,elimination half-lives,"The mean elimination half-lives of sparfloxacin were 34.9 and 38.5 h in group I and group II, respectively, versus 19.1 h in healthy volunteers.",Pharmacokinetics of sparfloxacin in patients with renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031038/),h,34.9,155858,DB01208,Sparfloxacin
,8031038,elimination half-lives,"The mean elimination half-lives of sparfloxacin were 34.9 and 38.5 h in group I and group II, respectively, versus 19.1 h in healthy volunteers.",Pharmacokinetics of sparfloxacin in patients with renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031038/),h,38.5,155859,DB01208,Sparfloxacin
,8031038,elimination half-lives,"The mean elimination half-lives of sparfloxacin were 34.9 and 38.5 h in group I and group II, respectively, versus 19.1 h in healthy volunteers.",Pharmacokinetics of sparfloxacin in patients with renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031038/),h,19.1,155860,DB01208,Sparfloxacin
,8031038,half-lives,"Conjugated drug half-lives were 23.7, 35.0, and 15.3 h, respectively.",Pharmacokinetics of sparfloxacin in patients with renal impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031038/),h,23.7,155861,DB01208,Sparfloxacin
,8031038,half-lives,"Conjugated drug half-lives were 23.7, 35.0, and 15.3 h, respectively.",Pharmacokinetics of sparfloxacin in patients with renal impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031038/),h,35.0,155862,DB01208,Sparfloxacin
,8031038,half-lives,"Conjugated drug half-lives were 23.7, 35.0, and 15.3 h, respectively.",Pharmacokinetics of sparfloxacin in patients with renal impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031038/),h,15.3,155863,DB01208,Sparfloxacin
,8031038,renal clearance,"The renal clearance of the drug was markedly reduced in the patients, with values of 6.8, 4.8, and 21.2 ml/min determined for group I, group II, and healthy subjects, respectively, for parent sparfloxacin and with values of 31.5, 14.0, and 327 ml/min for conjugated sparfloxacin.",Pharmacokinetics of sparfloxacin in patients with renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031038/),[ml] / [min],6.8,155864,DB01208,Sparfloxacin
,8031038,renal clearance,"The renal clearance of the drug was markedly reduced in the patients, with values of 6.8, 4.8, and 21.2 ml/min determined for group I, group II, and healthy subjects, respectively, for parent sparfloxacin and with values of 31.5, 14.0, and 327 ml/min for conjugated sparfloxacin.",Pharmacokinetics of sparfloxacin in patients with renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031038/),[ml] / [min],4.8,155865,DB01208,Sparfloxacin
,8031038,renal clearance,"The renal clearance of the drug was markedly reduced in the patients, with values of 6.8, 4.8, and 21.2 ml/min determined for group I, group II, and healthy subjects, respectively, for parent sparfloxacin and with values of 31.5, 14.0, and 327 ml/min for conjugated sparfloxacin.",Pharmacokinetics of sparfloxacin in patients with renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031038/),[ml] / [min],21.2,155866,DB01208,Sparfloxacin
,8031038,renal clearance,"The renal clearance of the drug was markedly reduced in the patients, with values of 6.8, 4.8, and 21.2 ml/min determined for group I, group II, and healthy subjects, respectively, for parent sparfloxacin and with values of 31.5, 14.0, and 327 ml/min for conjugated sparfloxacin.",Pharmacokinetics of sparfloxacin in patients with renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031038/),[ml] / [min],31.5,155867,DB01208,Sparfloxacin
,8031038,renal clearance,"The renal clearance of the drug was markedly reduced in the patients, with values of 6.8, 4.8, and 21.2 ml/min determined for group I, group II, and healthy subjects, respectively, for parent sparfloxacin and with values of 31.5, 14.0, and 327 ml/min for conjugated sparfloxacin.",Pharmacokinetics of sparfloxacin in patients with renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031038/),[ml] / [min],14.0,155868,DB01208,Sparfloxacin
,8031038,renal clearance,"The renal clearance of the drug was markedly reduced in the patients, with values of 6.8, 4.8, and 21.2 ml/min determined for group I, group II, and healthy subjects, respectively, for parent sparfloxacin and with values of 31.5, 14.0, and 327 ml/min for conjugated sparfloxacin.",Pharmacokinetics of sparfloxacin in patients with renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031038/),[ml] / [min],327,155869,DB01208,Sparfloxacin
,9163658,serum elimination half-lives,The median serum elimination half-lives were 17.3 h for SPX and 5.3 h for CPX.,"Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),h,17.3,168219,DB01208,Sparfloxacin
,9163658,serum elimination half-lives,The median serum elimination half-lives were 17.3 h for SPX and 5.3 h for CPX.,"Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),h,5.3,168220,DB01208,Sparfloxacin
,9163658,Peak levels,"Peak levels (median+/-68% confidence range) of CPX were attained in AMs (7.6+/-1.7 mg x L(-1)) at 5 h after admission, and in both ELF (2.13+/-0.91 mg x L(-1)) and PMNs (9.1+/-6.2 mg x L(-1)) at 2.5 h after administration.","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),[mg] / [l],7.6,168221,DB01208,Sparfloxacin
,9163658,Peak levels,"Peak levels (median+/-68% confidence range) of CPX were attained in AMs (7.6+/-1.7 mg x L(-1)) at 5 h after admission, and in both ELF (2.13+/-0.91 mg x L(-1)) and PMNs (9.1+/-6.2 mg x L(-1)) at 2.5 h after administration.","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),[mg] / [l],2.13,168222,DB01208,Sparfloxacin
,9163658,Peak levels,"Peak levels (median+/-68% confidence range) of CPX were attained in AMs (7.6+/-1.7 mg x L(-1)) at 5 h after admission, and in both ELF (2.13+/-0.91 mg x L(-1)) and PMNs (9.1+/-6.2 mg x L(-1)) at 2.5 h after administration.","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),[mg] / [l],9.1,168223,DB01208,Sparfloxacin
,9163658,peak levels,"SPX achieved comparable peak levels in PMNs (median+/-68% range, 9.4+/-1.1 mg x L(-1) at 5 h), but peak concentrations attained in AMs and ELF (35.1+/-15.4 and 32.2+/-28.2 mg x L(-1), respectively, at 24 h) were several times higher than those of CPX.","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),[mg] / [l],9.4,168224,DB01208,Sparfloxacin
,9163658,peak concentrations,"SPX achieved comparable peak levels in PMNs (median+/-68% range, 9.4+/-1.1 mg x L(-1) at 5 h), but peak concentrations attained in AMs and ELF (35.1+/-15.4 and 32.2+/-28.2 mg x L(-1), respectively, at 24 h) were several times higher than those of CPX.","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),[mg] / [l],35.1,168225,DB01208,Sparfloxacin
,9163658,peak concentrations,"SPX achieved comparable peak levels in PMNs (median+/-68% range, 9.4+/-1.1 mg x L(-1) at 5 h), but peak concentrations attained in AMs and ELF (35.1+/-15.4 and 32.2+/-28.2 mg x L(-1), respectively, at 24 h) were several times higher than those of CPX.","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),[mg] / [l],32.2,168226,DB01208,Sparfloxacin
,9163658,peak site to serum ratios,"SPX demonstrated substantially greater accumulation in all three sites than did CPX (peak site to serum ratios of 11.0+/-4.3, 65.5+/-28.4 and 63.0+/-66 versus 4.94+/-0.64, 10.6+/-3.7 and 10.6+/-3.7 for PMNs, AMs and ELF, respectively).","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),,11.0,168227,DB01208,Sparfloxacin
,9163658,peak site to serum ratios,"SPX demonstrated substantially greater accumulation in all three sites than did CPX (peak site to serum ratios of 11.0+/-4.3, 65.5+/-28.4 and 63.0+/-66 versus 4.94+/-0.64, 10.6+/-3.7 and 10.6+/-3.7 for PMNs, AMs and ELF, respectively).","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),,65.5,168228,DB01208,Sparfloxacin
,9163658,peak site to serum ratios,"SPX demonstrated substantially greater accumulation in all three sites than did CPX (peak site to serum ratios of 11.0+/-4.3, 65.5+/-28.4 and 63.0+/-66 versus 4.94+/-0.64, 10.6+/-3.7 and 10.6+/-3.7 for PMNs, AMs and ELF, respectively).","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),,63.0,168229,DB01208,Sparfloxacin
,9163658,peak site to serum ratios,"SPX demonstrated substantially greater accumulation in all three sites than did CPX (peak site to serum ratios of 11.0+/-4.3, 65.5+/-28.4 and 63.0+/-66 versus 4.94+/-0.64, 10.6+/-3.7 and 10.6+/-3.7 for PMNs, AMs and ELF, respectively).","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),,4.94,168230,DB01208,Sparfloxacin
,9163658,peak site to serum ratios,"SPX demonstrated substantially greater accumulation in all three sites than did CPX (peak site to serum ratios of 11.0+/-4.3, 65.5+/-28.4 and 63.0+/-66 versus 4.94+/-0.64, 10.6+/-3.7 and 10.6+/-3.7 for PMNs, AMs and ELF, respectively).","Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163658/),,10.6,168231,DB01208,Sparfloxacin
,7811321,refractive points,"The release of SPFX in water from four kinds of these coated fine granules containing 0, 25, 40 and 52% of L-HPC showed the pseudo first order kinetics, followed by the second phase, with refractive points between 0.25 and 0.5 h.",Role of low-substituted hydroxypropylcellulose in dissolution and bioavailability of novel fine granule system for masking bitter taste. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7811321/),h,0.25 and 0.5,176898,DB01208,Sparfloxacin
,9257738,maximum concentration of drug in serum (C(max)),"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),[μg] / [ml],1.27,181234,DB01208,Sparfloxacin
,9257738,time to C(max) (T(max)),"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),h,4.1,181235,DB01208,Sparfloxacin
,9257738,area under the concentration-time curve (AUC),"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),[h·μg] / [ml],35.0,181236,DB01208,Sparfloxacin
,9257738,mean residence time,"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),h,28.5,181237,DB01208,Sparfloxacin
,9257738,half-life (t1/2),"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),h,20,181238,DB01208,Sparfloxacin
,9257738,urinary recovery (UR x f),"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),%,11.0,181239,DB01208,Sparfloxacin
,9257738,ratio,"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),,2.6,181240,DB01208,Sparfloxacin
,9257738,T(max),For the cisapride group there was a significant decrease in the sparfloxacin T(max) (1.9 +/- 2.1 h) and a significant increase in C(max) (1.74 +/- 0.73 microg/ml).,Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),h,1.9,181241,DB01208,Sparfloxacin
,9257738,C(max),For the cisapride group there was a significant decrease in the sparfloxacin T(max) (1.9 +/- 2.1 h) and a significant increase in C(max) (1.74 +/- 0.73 microg/ml).,Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),[μg] / [ml],1.74,181242,DB01208,Sparfloxacin
,9257738,C(max),"Significant differences in the values for the group receiving sucralfate compared to the values for the group receiving sparfloxacin alone were found: C(max), 0.77 +/- 0.31 microg/ml; AUC, 18.6 +/- 5.8 microg x h/ml; t1/2, 26 +/- 10 h; and UR x f, 5.8 +/- 1.8%.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),[μg] / [ml],0.77,181243,DB01208,Sparfloxacin
,9257738,AUC,"Significant differences in the values for the group receiving sucralfate compared to the values for the group receiving sparfloxacin alone were found: C(max), 0.77 +/- 0.31 microg/ml; AUC, 18.6 +/- 5.8 microg x h/ml; t1/2, 26 +/- 10 h; and UR x f, 5.8 +/- 1.8%.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),[h·μg] / [ml],18.6,181244,DB01208,Sparfloxacin
,9257738,t1/2,"Significant differences in the values for the group receiving sucralfate compared to the values for the group receiving sparfloxacin alone were found: C(max), 0.77 +/- 0.31 microg/ml; AUC, 18.6 +/- 5.8 microg x h/ml; t1/2, 26 +/- 10 h; and UR x f, 5.8 +/- 1.8%.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),h,26,181245,DB01208,Sparfloxacin
,9257738,UR x f,"Significant differences in the values for the group receiving sucralfate compared to the values for the group receiving sparfloxacin alone were found: C(max), 0.77 +/- 0.31 microg/ml; AUC, 18.6 +/- 5.8 microg x h/ml; t1/2, 26 +/- 10 h; and UR x f, 5.8 +/- 1.8%.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),%,5.8,181246,DB01208,Sparfloxacin
,11212495,b,Thus bacteriological efficacy amounted to 87.5 per cent.,[Clinical and laboratory efficacy of the novel difluoroquinolone Sparflo (sparfloxacin) in therapy of skin and soft tissue infections]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11212495/),-1,87.5,192075,DB01208,Sparfloxacin
,11212495,elimination half-life,Pharmacokinetic data demonstrates long-term sparfloxacin circulation in the organism of patients with burns--elimination half-life amounted to 20 hours.,[Clinical and laboratory efficacy of the novel difluoroquinolone Sparflo (sparfloxacin) in therapy of skin and soft tissue infections]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11212495/),h,20,192076,DB01208,Sparfloxacin
,9559783,rates of survival,"In accord with the pulmonary clearance results, the rates of survival for mice treated with HSR-903, sparfloxacin, levofloxacin, ciprofloxacin, and benzylpenicillin were 50, 30, 10, 0, and 0%, respectively, 14 days after being infected with penicillin-resistant S. pneumoniae.","In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559783/),%,50,193204,DB01208,Sparfloxacin
,9559783,rates of survival,"In accord with the pulmonary clearance results, the rates of survival for mice treated with HSR-903, sparfloxacin, levofloxacin, ciprofloxacin, and benzylpenicillin were 50, 30, 10, 0, and 0%, respectively, 14 days after being infected with penicillin-resistant S. pneumoniae.","In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559783/),%,30,193205,DB01208,Sparfloxacin
,9559783,rates of survival,"In accord with the pulmonary clearance results, the rates of survival for mice treated with HSR-903, sparfloxacin, levofloxacin, ciprofloxacin, and benzylpenicillin were 50, 30, 10, 0, and 0%, respectively, 14 days after being infected with penicillin-resistant S. pneumoniae.","In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559783/),%,10,193206,DB01208,Sparfloxacin
,9559783,rates of survival,"In accord with the pulmonary clearance results, the rates of survival for mice treated with HSR-903, sparfloxacin, levofloxacin, ciprofloxacin, and benzylpenicillin were 50, 30, 10, 0, and 0%, respectively, 14 days after being infected with penicillin-resistant S. pneumoniae.","In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559783/),%,0,193207,DB01208,Sparfloxacin
less,11418508,C(max)/MIC ratio,"Resistance (at least four-fold increase in MIC) developed when the C(max)/MIC ratio was less than four or the AUC above the MIC was less than 10, and the resulting cultures regrew fully.",The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418508/),,four,194647,DB01208,Sparfloxacin
less,11418508,AUC above the MIC,"Resistance (at least four-fold increase in MIC) developed when the C(max)/MIC ratio was less than four or the AUC above the MIC was less than 10, and the resulting cultures regrew fully.",The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418508/),,10,194648,DB01208,Sparfloxacin
higher,11418508,C(max)/MIC ratio,"In contrast, pneumococci with a two- to four-fold increase in sparfloxacin MIC were selected in the presence of serum concentrations of sparfloxacin despite a C(max)/MIC ratio higher than 12, but these isolates remained clinically susceptible by breakpoint MIC and their growth was inhibited by repeated dosage of sparfloxacin.",The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11418508/),,12,194649,DB01208,Sparfloxacin
,9181388,AUC0-24,"The highest mean AUC0-24 was found in the prostate gland, followed by left epididymis, right epididymis, serum, right testis, and left testis (190, 79, 60, 28, 12, and 9 mg/kg x h, respectively).",Tissue penetration of sparfloxacin in a rat model of experimental Escherichia coli epididymitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9181388/),[mg] / [h·kg],190,197197,DB01208,Sparfloxacin
,9181388,AUC0-24,"The highest mean AUC0-24 was found in the prostate gland, followed by left epididymis, right epididymis, serum, right testis, and left testis (190, 79, 60, 28, 12, and 9 mg/kg x h, respectively).",Tissue penetration of sparfloxacin in a rat model of experimental Escherichia coli epididymitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9181388/),[mg] / [h·kg],79,197198,DB01208,Sparfloxacin
,9181388,AUC0-24,"The highest mean AUC0-24 was found in the prostate gland, followed by left epididymis, right epididymis, serum, right testis, and left testis (190, 79, 60, 28, 12, and 9 mg/kg x h, respectively).",Tissue penetration of sparfloxacin in a rat model of experimental Escherichia coli epididymitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9181388/),[mg] / [h·kg],60,197199,DB01208,Sparfloxacin
,9181388,AUC0-24,"The highest mean AUC0-24 was found in the prostate gland, followed by left epididymis, right epididymis, serum, right testis, and left testis (190, 79, 60, 28, 12, and 9 mg/kg x h, respectively).",Tissue penetration of sparfloxacin in a rat model of experimental Escherichia coli epididymitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9181388/),[mg] / [h·kg],28,197200,DB01208,Sparfloxacin
,9181388,AUC0-24,"The highest mean AUC0-24 was found in the prostate gland, followed by left epididymis, right epididymis, serum, right testis, and left testis (190, 79, 60, 28, 12, and 9 mg/kg x h, respectively).",Tissue penetration of sparfloxacin in a rat model of experimental Escherichia coli epididymitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9181388/),[mg] / [h·kg],12,197201,DB01208,Sparfloxacin
,9181388,AUC0-24,"The highest mean AUC0-24 was found in the prostate gland, followed by left epididymis, right epididymis, serum, right testis, and left testis (190, 79, 60, 28, 12, and 9 mg/kg x h, respectively).",Tissue penetration of sparfloxacin in a rat model of experimental Escherichia coli epididymitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9181388/),[mg] / [h·kg],9,197202,DB01208,Sparfloxacin
,8067740,MIC for 90%,"A-80556 was particularly active against Staphylococcus aureus (MIC for 90% of isolates [MIC90], 0.12 microgram/ml, relative to fluoroquinolone-susceptible strains) and Streptococcus pneumoniae (MIC90, 0.12 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.12,200513,DB01208,Sparfloxacin
,8067740,MIC90],"A-80556 was particularly active against Staphylococcus aureus (MIC for 90% of isolates [MIC90], 0.12 microgram/ml, relative to fluoroquinolone-susceptible strains) and Streptococcus pneumoniae (MIC90, 0.12 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.12,200514,DB01208,Sparfloxacin
,8067740,MIC90,"A-80556 was particularly active against Staphylococcus aureus (MIC for 90% of isolates [MIC90], 0.12 microgram/ml, relative to fluoroquinolone-susceptible strains) and Streptococcus pneumoniae (MIC90, 0.12 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.12,200515,DB01208,Sparfloxacin
,8067740,MIC90,"A-80556 was also the most active of the quinolones tested against ciprofloxacin-resistant S. aureus, with an MIC90 of 4.0 micrograms/ml; that of ciprofloxacin was > 128 micrograms/ml.","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],4.0,200516,DB01208,Sparfloxacin
>,8067740,MIC90,"A-80556 was also the most active of the quinolones tested against ciprofloxacin-resistant S. aureus, with an MIC90 of 4.0 micrograms/ml; that of ciprofloxacin was > 128 micrograms/ml.","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],128,200517,DB01208,Sparfloxacin
,8067740,MIC90,"A-80556 was slightly less active against Escherichia coli (MIC90, 0.06 microgram/ml) and other enteric organisms than ciprofloxacin (MIC90 for E. coli, < or = 0.03 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.06,200518,DB01208,Sparfloxacin
< or =,8067740,MIC90,"A-80556 was slightly less active against Escherichia coli (MIC90, 0.06 microgram/ml) and other enteric organisms than ciprofloxacin (MIC90 for E. coli, < or = 0.03 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.03,200519,DB01208,Sparfloxacin
,8067740,MIC90,"A-80556 was slightly less active against Pseudomonas aeruginosa (MIC90, 4.0 micrograms/ml) than ciprofloxacin (MIC90, 2.0 micrograms/ml) and more active against Acinetobacter spp. (respective MIC90s, 0.12 and 0.5 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],4.0,200520,DB01208,Sparfloxacin
,8067740,MIC90,"A-80556 was slightly less active against Pseudomonas aeruginosa (MIC90, 4.0 micrograms/ml) than ciprofloxacin (MIC90, 2.0 micrograms/ml) and more active against Acinetobacter spp. (respective MIC90s, 0.12 and 0.5 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],2.0,200521,DB01208,Sparfloxacin
,8067740,MIC90s,"A-80556 was slightly less active against Pseudomonas aeruginosa (MIC90, 4.0 micrograms/ml) than ciprofloxacin (MIC90, 2.0 micrograms/ml) and more active against Acinetobacter spp. (respective MIC90s, 0.12 and 0.5 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.12,200522,DB01208,Sparfloxacin
,8067740,MIC90s,"A-80556 was slightly less active against Pseudomonas aeruginosa (MIC90, 4.0 micrograms/ml) than ciprofloxacin (MIC90, 2.0 micrograms/ml) and more active against Acinetobacter spp. (respective MIC90s, 0.12 and 0.5 microgram/ml).","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],0.5,200523,DB01208,Sparfloxacin
,8067740,MIC90,"Against Bacteroides fragilis, the MIC90 of A-80556 was 2.0 micrograms/ml; that of ciprofloxacin was 16 micrograms/ml.","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],2.0,200524,DB01208,Sparfloxacin
,8067740,MIC90,"Against Bacteroides fragilis, the MIC90 of A-80556 was 2.0 micrograms/ml; that of ciprofloxacin was 16 micrograms/ml.","In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067740/),[μg] / [ml],16,200525,DB01208,Sparfloxacin
,1929255,total body clearance,"The total body clearance of theophylline after coadministration of sparfloxacin, 42.81 +/- 6.64 ml/h/kg (mean +/- standard error of the mean), was not significantly different from that after the administration of theophylline alone, 47.11 +/- 7.61 ml/h/kg.","Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929255/),[ml] / [h·kg],42.81,201113,DB01208,Sparfloxacin
,1929255,total body clearance,"The total body clearance of theophylline after coadministration of sparfloxacin, 42.81 +/- 6.64 ml/h/kg (mean +/- standard error of the mean), was not significantly different from that after the administration of theophylline alone, 47.11 +/- 7.61 ml/h/kg.","Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929255/),[ml] / [h·kg],47.11,201114,DB01208,Sparfloxacin
,17190680,apparent volume of distribution,"2. The apparent volume of distribution, total body clearance, mean residence time and elimination half-life following oral administration were 2.411/kg, 4.55 ml/min per kg, 10.54 and 5.94 h, respectively.",Pharmacokinetics of sparfloxacin in broiler chicken. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190680/),1/[kg],2.411,207870,DB01208,Sparfloxacin
,17190680,total body clearance,"2. The apparent volume of distribution, total body clearance, mean residence time and elimination half-life following oral administration were 2.411/kg, 4.55 ml/min per kg, 10.54 and 5.94 h, respectively.",Pharmacokinetics of sparfloxacin in broiler chicken. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190680/),[ml] / [kg·min],4.55,207871,DB01208,Sparfloxacin
,17190680,total body clearance,"2. The apparent volume of distribution, total body clearance, mean residence time and elimination half-life following oral administration were 2.411/kg, 4.55 ml/min per kg, 10.54 and 5.94 h, respectively.",Pharmacokinetics of sparfloxacin in broiler chicken. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190680/),h,10.54,207872,DB01208,Sparfloxacin
,17190680,mean residence time,"2. The apparent volume of distribution, total body clearance, mean residence time and elimination half-life following oral administration were 2.411/kg, 4.55 ml/min per kg, 10.54 and 5.94 h, respectively.",Pharmacokinetics of sparfloxacin in broiler chicken. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190680/),[ml] / [kg·min],4.55,207873,DB01208,Sparfloxacin
,17190680,mean residence time,"2. The apparent volume of distribution, total body clearance, mean residence time and elimination half-life following oral administration were 2.411/kg, 4.55 ml/min per kg, 10.54 and 5.94 h, respectively.",Pharmacokinetics of sparfloxacin in broiler chicken. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190680/),h,10.54,207874,DB01208,Sparfloxacin
,17190680,elimination half-life,"2. The apparent volume of distribution, total body clearance, mean residence time and elimination half-life following oral administration were 2.411/kg, 4.55 ml/min per kg, 10.54 and 5.94 h, respectively.",Pharmacokinetics of sparfloxacin in broiler chicken. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190680/),h,5.94,207875,DB01208,Sparfloxacin
,17190680,Oral bioavailability,Oral bioavailability was 61.7%. 3. Sparfloxacin was found to possess clinically useful pharmacokinetic properties.,Pharmacokinetics of sparfloxacin in broiler chicken. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17190680/),%,61.7,207876,DB01208,Sparfloxacin
,18655224,flow rate,"The resolution of peaks was achieved with phosphate buffer (pH 2.5)-acetonitrile (80:20, v/v) at a flow rate of 1 mL/min on a Kromasil C(18) column.","Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655224/),[ml] / [min],1,208521,DB01208,Sparfloxacin
,18655224,total chromatographic run time,"The total chromatographic run time was 18.0 min and the simultaneous elution of GFC, SFC, MFC and IS occurred at approximately 10.8, 12.8, 17.0 and 6.0 min, respectively.","Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655224/),min,18.0,208522,DB01208,Sparfloxacin
,12356277,distribution volume atsteadystate (Vd(ss)),"Following intravenous administration of these quinolonesto rats, the distribution volume atsteadystate (Vd(ss)) of PZFX wasfound to be 0.945 L kg(-1), whereas for OFLX and SPFX it was 1.83 and 3.42 L kg(-1), respectively.",Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12356277/),[l] / [kg],0.945,213952,DB01208,Sparfloxacin
,12356277,distribution volume atsteadystate (Vd(ss)),"Following intravenous administration of these quinolonesto rats, the distribution volume atsteadystate (Vd(ss)) of PZFX wasfound to be 0.945 L kg(-1), whereas for OFLX and SPFX it was 1.83 and 3.42 L kg(-1), respectively.",Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12356277/),[l] / [kg],1.83,213953,DB01208,Sparfloxacin
,12356277,distribution volume atsteadystate (Vd(ss)),"Following intravenous administration of these quinolonesto rats, the distribution volume atsteadystate (Vd(ss)) of PZFX wasfound to be 0.945 L kg(-1), whereas for OFLX and SPFX it was 1.83 and 3.42 L kg(-1), respectively.",Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12356277/),[l] / [kg],3.42,213954,DB01208,Sparfloxacin
,12356277,tissue CLuptake,"In contrast, the tissue CLuptake of PZFX in the muscle (0.012 mL min(-1) g(-1)) was significantly lowerthan that of OFLX and SPFX (0.118 and 0.195 mL min(-1) g(-1), respectively).",Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12356277/),[ml] / [g·min],0.012,213955,DB01208,Sparfloxacin
,12356277,tissue CLuptake,"In contrast, the tissue CLuptake of PZFX in the muscle (0.012 mL min(-1) g(-1)) was significantly lowerthan that of OFLX and SPFX (0.118 and 0.195 mL min(-1) g(-1), respectively).",Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12356277/),[ml] / [g·min],0.118,213956,DB01208,Sparfloxacin
,12356277,tissue CLuptake,"In contrast, the tissue CLuptake of PZFX in the muscle (0.012 mL min(-1) g(-1)) was significantly lowerthan that of OFLX and SPFX (0.118 and 0.195 mL min(-1) g(-1), respectively).",Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12356277/),[ml] / [g·min],0.195,213957,DB01208,Sparfloxacin
,10211539,steady-state area under the concentration-time curve over 24 hours,Mean values for steady-state area under the concentration-time curve over 24 hours for the 2 treatments were virtually identical: 28.4 ng/h per mL(-1) for digoxin administered with placebo and 28.9 ng/h per mL(-1) for digoxin administered concomitantly with sparfloxacin.,Pharmacokinetic interaction of sparfloxacin and digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211539/),[h·ng] / [ml],28.4,228369,DB01208,Sparfloxacin
,10211539,steady-state area under the concentration-time curve over 24 hours,Mean values for steady-state area under the concentration-time curve over 24 hours for the 2 treatments were virtually identical: 28.4 ng/h per mL(-1) for digoxin administered with placebo and 28.9 ng/h per mL(-1) for digoxin administered concomitantly with sparfloxacin.,Pharmacokinetic interaction of sparfloxacin and digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211539/),[h·ng] / [ml],28.9,228370,DB01208,Sparfloxacin
,10211539,steady-state maximum plasma concentrations,"Mean steady-state maximum plasma concentrations were 3.91 and 3.59 ng/mL for digoxin with placebo and digoxin with sparfloxacin, respectively.",Pharmacokinetic interaction of sparfloxacin and digoxin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211539/),[ng] / [ml],3.91,228371,DB01208,Sparfloxacin
,10211539,steady-state maximum plasma concentrations,"Mean steady-state maximum plasma concentrations were 3.91 and 3.59 ng/mL for digoxin with placebo and digoxin with sparfloxacin, respectively.",Pharmacokinetic interaction of sparfloxacin and digoxin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211539/),[ng] / [ml],3.59,228372,DB01208,Sparfloxacin
,10211539,steady-state trough plasma digoxin concentrations,"Mean steady-state trough plasma digoxin concentrations for the 2 treatments were 0.87 and 0.89 ng/mL, respectively.",Pharmacokinetic interaction of sparfloxacin and digoxin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211539/),[ng] / [ml],0.87,228373,DB01208,Sparfloxacin
,10211539,steady-state trough plasma digoxin concentrations,"Mean steady-state trough plasma digoxin concentrations for the 2 treatments were 0.87 and 0.89 ng/mL, respectively.",Pharmacokinetic interaction of sparfloxacin and digoxin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211539/),[ng] / [ml],0.89,228374,DB01208,Sparfloxacin
,10211539,times to steady-state maximum plasma concentrations,Mean times to steady-state maximum plasma concentrations were identical at 0.89 hours for both treatments.,Pharmacokinetic interaction of sparfloxacin and digoxin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211539/),h,0.89,228375,DB01208,Sparfloxacin
,10211539,steady-state oral clearance,Mean steady-state oral clearance was 10.6 L/h for digoxin alone and 10.4 L/h for digoxin with sparfloxacin.,Pharmacokinetic interaction of sparfloxacin and digoxin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211539/),[l] / [h],10.6,228376,DB01208,Sparfloxacin
,10211539,steady-state oral clearance,Mean steady-state oral clearance was 10.6 L/h for digoxin alone and 10.4 L/h for digoxin with sparfloxacin.,Pharmacokinetic interaction of sparfloxacin and digoxin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211539/),[l] / [h],10.4,228377,DB01208,Sparfloxacin
,26046921,total run time,The total run time was 3.5 min.,A validated HPLC-MS/MS method for the quantification of caderofloxacin in human plasma and its application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26046921/),min,3.5,228723,DB01208,Sparfloxacin
,9765852,MIC,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,10.3,232497,DB01208,Sparfloxacin
,9765852,MIC,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,28.0,232498,DB01208,Sparfloxacin
,9765852,MIC,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,2,232499,DB01208,Sparfloxacin
,9765852,MIC x 4,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,14.7,232500,DB01208,Sparfloxacin
,9765852,MIC x 4,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,17.7,232501,DB01208,Sparfloxacin
,9765852,MIC x 4,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,28.0,232502,DB01208,Sparfloxacin
,9765852,MIC x 4,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,62.0,232503,DB01208,Sparfloxacin
,9765852,MIC x 4,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,71,232504,DB01208,Sparfloxacin
,9765852,MIC x 4,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,2,232505,DB01208,Sparfloxacin
,9765852,MIC x 4,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,15.0,232506,DB01208,Sparfloxacin
,9765852,MIC x 4,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,28,232507,DB01208,Sparfloxacin
,9765852,MIC x 8,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,28.0,232508,DB01208,Sparfloxacin
,9765852,MIC x 8,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,62.0,232509,DB01208,Sparfloxacin
,9765852,MIC x 8,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,71,232510,DB01208,Sparfloxacin
,9765852,MIC x 8,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,2,232511,DB01208,Sparfloxacin
,9765852,MIC x 8,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,15.0,232512,DB01208,Sparfloxacin
,9765852,MIC x 8,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,28,232513,DB01208,Sparfloxacin
,14661070,plasma maximum concentration ( C(max)),"Across dose and study day, mean garenoxacin plasma maximum concentration ( C(max)) and area under the concentration-time curve (AUC(tau)) values were in the range 12-26 mg/l and 33-133 mgxh/l, respectively.",Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14661070/),[mg] / [l],12-26,233549,DB01208,Sparfloxacin
,14661070,area under the concentration-time curve (AUC(tau)),"Across dose and study day, mean garenoxacin plasma maximum concentration ( C(max)) and area under the concentration-time curve (AUC(tau)) values were in the range 12-26 mg/l and 33-133 mgxh/l, respectively.",Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14661070/),[h·mg] / [l],33-133,233550,DB01208,Sparfloxacin
,14661070,T(max),Values determined for T(max) (0.25-1.0 h) and T(1/2) (3.8-6.4 h) of garenoxacin in plasma did not vary with dose or study day.,Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14661070/),h,0.25-1.0,233551,DB01208,Sparfloxacin
,14661070,T(1/2),Values determined for T(max) (0.25-1.0 h) and T(1/2) (3.8-6.4 h) of garenoxacin in plasma did not vary with dose or study day.,Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14661070/),h,3.8-6.4,233552,DB01208,Sparfloxacin
,16530028,absolute recovery,The mean absolute recovery for human serum was 98.8+/-5.7%.,Improvement and validation of an HPLC method for examining the effects of the MDR1 gene polymorphism on sparfloxacin pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16530028/),%,98.8,234899,DB01208,Sparfloxacin
,9624496,concentrations,"The concentrations in plasma measured 0.75, 1.5, 3, 6, 24, and 48 h after the administration of an oral dose of 1,800 mg of sparfloxacin/kg were 10.9 +/- 1.5, 15.9 +/- 1.6, 19.1 +/- 1.7, 14.9 +/- 3.1, 4.1 +/- 0.6, and 0.46 +/- 0.37 mg/liter, respectively (mean +/- SD; n = 3 to 4 per group).",Chondrotoxicity and toxicokinetics of sparfloxacin in juvenile rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624496/),[mg] / [l],10.9,243238,DB01208,Sparfloxacin
,9624496,concentrations,"The concentrations in plasma measured 0.75, 1.5, 3, 6, 24, and 48 h after the administration of an oral dose of 1,800 mg of sparfloxacin/kg were 10.9 +/- 1.5, 15.9 +/- 1.6, 19.1 +/- 1.7, 14.9 +/- 3.1, 4.1 +/- 0.6, and 0.46 +/- 0.37 mg/liter, respectively (mean +/- SD; n = 3 to 4 per group).",Chondrotoxicity and toxicokinetics of sparfloxacin in juvenile rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624496/),[mg] / [l],15.9,243239,DB01208,Sparfloxacin
,9624496,concentrations,"The concentrations in plasma measured 0.75, 1.5, 3, 6, 24, and 48 h after the administration of an oral dose of 1,800 mg of sparfloxacin/kg were 10.9 +/- 1.5, 15.9 +/- 1.6, 19.1 +/- 1.7, 14.9 +/- 3.1, 4.1 +/- 0.6, and 0.46 +/- 0.37 mg/liter, respectively (mean +/- SD; n = 3 to 4 per group).",Chondrotoxicity and toxicokinetics of sparfloxacin in juvenile rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624496/),[mg] / [l],19.1,243240,DB01208,Sparfloxacin
,9624496,concentrations,"The concentrations in plasma measured 0.75, 1.5, 3, 6, 24, and 48 h after the administration of an oral dose of 1,800 mg of sparfloxacin/kg were 10.9 +/- 1.5, 15.9 +/- 1.6, 19.1 +/- 1.7, 14.9 +/- 3.1, 4.1 +/- 0.6, and 0.46 +/- 0.37 mg/liter, respectively (mean +/- SD; n = 3 to 4 per group).",Chondrotoxicity and toxicokinetics of sparfloxacin in juvenile rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624496/),[mg] / [l],14.9,243241,DB01208,Sparfloxacin
,9624496,concentrations,"The concentrations in plasma measured 0.75, 1.5, 3, 6, 24, and 48 h after the administration of an oral dose of 1,800 mg of sparfloxacin/kg were 10.9 +/- 1.5, 15.9 +/- 1.6, 19.1 +/- 1.7, 14.9 +/- 3.1, 4.1 +/- 0.6, and 0.46 +/- 0.37 mg/liter, respectively (mean +/- SD; n = 3 to 4 per group).",Chondrotoxicity and toxicokinetics of sparfloxacin in juvenile rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624496/),[mg] / [l],4.1,243242,DB01208,Sparfloxacin
,9624496,concentrations,"The concentrations in plasma measured 0.75, 1.5, 3, 6, 24, and 48 h after the administration of an oral dose of 1,800 mg of sparfloxacin/kg were 10.9 +/- 1.5, 15.9 +/- 1.6, 19.1 +/- 1.7, 14.9 +/- 3.1, 4.1 +/- 0.6, and 0.46 +/- 0.37 mg/liter, respectively (mean +/- SD; n = 3 to 4 per group).",Chondrotoxicity and toxicokinetics of sparfloxacin in juvenile rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624496/),[mg] / [l],0.46,243243,DB01208,Sparfloxacin
,1663355,tmax,"Plasma levels after the 1st and 14th administration were similar in terms of tmax (1 h), Cmax (around 1.35 micrograms eq/ml), T1/2 (3-4 h) and AUC (about 7.3 micrograms eq h/ml).",Disposition and metabolism of [14C]sparfloxacin after repeated administration in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663355/),h,1,245910,DB01208,Sparfloxacin
,1663355,Cmax,"Plasma levels after the 1st and 14th administration were similar in terms of tmax (1 h), Cmax (around 1.35 micrograms eq/ml), T1/2 (3-4 h) and AUC (about 7.3 micrograms eq h/ml).",Disposition and metabolism of [14C]sparfloxacin after repeated administration in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663355/),[eq·μg] / [ml],1.35,245911,DB01208,Sparfloxacin
,1663355,T1/2,"Plasma levels after the 1st and 14th administration were similar in terms of tmax (1 h), Cmax (around 1.35 micrograms eq/ml), T1/2 (3-4 h) and AUC (about 7.3 micrograms eq h/ml).",Disposition and metabolism of [14C]sparfloxacin after repeated administration in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663355/),h,3-4,245912,DB01208,Sparfloxacin
,1663355,AUC,"Plasma levels after the 1st and 14th administration were similar in terms of tmax (1 h), Cmax (around 1.35 micrograms eq/ml), T1/2 (3-4 h) and AUC (about 7.3 micrograms eq h/ml).",Disposition and metabolism of [14C]sparfloxacin after repeated administration in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663355/),[eq·h·μg] / [ml],7.3,245913,DB01208,Sparfloxacin
,8203837,peak concentration,A mean peak concentration in serum (400-mg dose) of 0.56 +/- 0.13 mg/liter was measured 3.52 +/- 0.98 h after administration.,Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8203837/),[mg] / [l],0.56,262104,DB01208,Sparfloxacin
,8203837,area under the curve,"Pharmacokinetic parameters (measured by high-performance liquid chromatography) were based on an open, one-compartment model and resulted in the following day 1 (calculated for the 200-mg dose), day 4 (recalculated for a single dose), and day 8 values (mean +/- standard deviation): area under the curve, 16.4 +/- 2.3 (day 1) and 18.3 +/- 5.1 (day 4) mg.h/liter; elimination half-life, 18.3 +/- 3.9 h; steady-state volume of distribution, 4.7 +/- 1.4 (day 1) and 4.3 +/- 1.2 (day 8) liters/kg; apparent total clearance, 201 +/- 31 (day 1) and 190 +/- 51 (day 4) ml/min; renal clearance, 19.1 +/- 5.8 (day 1) and 23.2 +/- 19.4 (day 4) ml/min.",Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8203837/),[h·mg] / [l],16.4,262105,DB01208,Sparfloxacin
,8203837,area under the curve,"Pharmacokinetic parameters (measured by high-performance liquid chromatography) were based on an open, one-compartment model and resulted in the following day 1 (calculated for the 200-mg dose), day 4 (recalculated for a single dose), and day 8 values (mean +/- standard deviation): area under the curve, 16.4 +/- 2.3 (day 1) and 18.3 +/- 5.1 (day 4) mg.h/liter; elimination half-life, 18.3 +/- 3.9 h; steady-state volume of distribution, 4.7 +/- 1.4 (day 1) and 4.3 +/- 1.2 (day 8) liters/kg; apparent total clearance, 201 +/- 31 (day 1) and 190 +/- 51 (day 4) ml/min; renal clearance, 19.1 +/- 5.8 (day 1) and 23.2 +/- 19.4 (day 4) ml/min.",Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8203837/),[h·mg] / [l],18.3,262106,DB01208,Sparfloxacin
,8203837,elimination half-life,"Pharmacokinetic parameters (measured by high-performance liquid chromatography) were based on an open, one-compartment model and resulted in the following day 1 (calculated for the 200-mg dose), day 4 (recalculated for a single dose), and day 8 values (mean +/- standard deviation): area under the curve, 16.4 +/- 2.3 (day 1) and 18.3 +/- 5.1 (day 4) mg.h/liter; elimination half-life, 18.3 +/- 3.9 h; steady-state volume of distribution, 4.7 +/- 1.4 (day 1) and 4.3 +/- 1.2 (day 8) liters/kg; apparent total clearance, 201 +/- 31 (day 1) and 190 +/- 51 (day 4) ml/min; renal clearance, 19.1 +/- 5.8 (day 1) and 23.2 +/- 19.4 (day 4) ml/min.",Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8203837/),h,18.3,262107,DB01208,Sparfloxacin
,8203837,steady-state volume of distribution,"Pharmacokinetic parameters (measured by high-performance liquid chromatography) were based on an open, one-compartment model and resulted in the following day 1 (calculated for the 200-mg dose), day 4 (recalculated for a single dose), and day 8 values (mean +/- standard deviation): area under the curve, 16.4 +/- 2.3 (day 1) and 18.3 +/- 5.1 (day 4) mg.h/liter; elimination half-life, 18.3 +/- 3.9 h; steady-state volume of distribution, 4.7 +/- 1.4 (day 1) and 4.3 +/- 1.2 (day 8) liters/kg; apparent total clearance, 201 +/- 31 (day 1) and 190 +/- 51 (day 4) ml/min; renal clearance, 19.1 +/- 5.8 (day 1) and 23.2 +/- 19.4 (day 4) ml/min.",Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8203837/),[l] / [kg],4.7,262108,DB01208,Sparfloxacin
,8203837,steady-state volume of distribution,"Pharmacokinetic parameters (measured by high-performance liquid chromatography) were based on an open, one-compartment model and resulted in the following day 1 (calculated for the 200-mg dose), day 4 (recalculated for a single dose), and day 8 values (mean +/- standard deviation): area under the curve, 16.4 +/- 2.3 (day 1) and 18.3 +/- 5.1 (day 4) mg.h/liter; elimination half-life, 18.3 +/- 3.9 h; steady-state volume of distribution, 4.7 +/- 1.4 (day 1) and 4.3 +/- 1.2 (day 8) liters/kg; apparent total clearance, 201 +/- 31 (day 1) and 190 +/- 51 (day 4) ml/min; renal clearance, 19.1 +/- 5.8 (day 1) and 23.2 +/- 19.4 (day 4) ml/min.",Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8203837/),[l] / [kg],4.3,262109,DB01208,Sparfloxacin
,8203837,apparent total clearance,"Pharmacokinetic parameters (measured by high-performance liquid chromatography) were based on an open, one-compartment model and resulted in the following day 1 (calculated for the 200-mg dose), day 4 (recalculated for a single dose), and day 8 values (mean +/- standard deviation): area under the curve, 16.4 +/- 2.3 (day 1) and 18.3 +/- 5.1 (day 4) mg.h/liter; elimination half-life, 18.3 +/- 3.9 h; steady-state volume of distribution, 4.7 +/- 1.4 (day 1) and 4.3 +/- 1.2 (day 8) liters/kg; apparent total clearance, 201 +/- 31 (day 1) and 190 +/- 51 (day 4) ml/min; renal clearance, 19.1 +/- 5.8 (day 1) and 23.2 +/- 19.4 (day 4) ml/min.",Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8203837/),[ml] / [min],201,262110,DB01208,Sparfloxacin
,8203837,apparent total clearance,"Pharmacokinetic parameters (measured by high-performance liquid chromatography) were based on an open, one-compartment model and resulted in the following day 1 (calculated for the 200-mg dose), day 4 (recalculated for a single dose), and day 8 values (mean +/- standard deviation): area under the curve, 16.4 +/- 2.3 (day 1) and 18.3 +/- 5.1 (day 4) mg.h/liter; elimination half-life, 18.3 +/- 3.9 h; steady-state volume of distribution, 4.7 +/- 1.4 (day 1) and 4.3 +/- 1.2 (day 8) liters/kg; apparent total clearance, 201 +/- 31 (day 1) and 190 +/- 51 (day 4) ml/min; renal clearance, 19.1 +/- 5.8 (day 1) and 23.2 +/- 19.4 (day 4) ml/min.",Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8203837/),[ml] / [min],190,262111,DB01208,Sparfloxacin
,8203837,renal clearance,"Pharmacokinetic parameters (measured by high-performance liquid chromatography) were based on an open, one-compartment model and resulted in the following day 1 (calculated for the 200-mg dose), day 4 (recalculated for a single dose), and day 8 values (mean +/- standard deviation): area under the curve, 16.4 +/- 2.3 (day 1) and 18.3 +/- 5.1 (day 4) mg.h/liter; elimination half-life, 18.3 +/- 3.9 h; steady-state volume of distribution, 4.7 +/- 1.4 (day 1) and 4.3 +/- 1.2 (day 8) liters/kg; apparent total clearance, 201 +/- 31 (day 1) and 190 +/- 51 (day 4) ml/min; renal clearance, 19.1 +/- 5.8 (day 1) and 23.2 +/- 19.4 (day 4) ml/min.",Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8203837/),[ml] / [min],19.1,262112,DB01208,Sparfloxacin
,8203837,renal clearance,"Pharmacokinetic parameters (measured by high-performance liquid chromatography) were based on an open, one-compartment model and resulted in the following day 1 (calculated for the 200-mg dose), day 4 (recalculated for a single dose), and day 8 values (mean +/- standard deviation): area under the curve, 16.4 +/- 2.3 (day 1) and 18.3 +/- 5.1 (day 4) mg.h/liter; elimination half-life, 18.3 +/- 3.9 h; steady-state volume of distribution, 4.7 +/- 1.4 (day 1) and 4.3 +/- 1.2 (day 8) liters/kg; apparent total clearance, 201 +/- 31 (day 1) and 190 +/- 51 (day 4) ml/min; renal clearance, 19.1 +/- 5.8 (day 1) and 23.2 +/- 19.4 (day 4) ml/min.",Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8203837/),[ml] / [min],23.2,262113,DB01208,Sparfloxacin
,8203837,Recovery in urine,Recovery in urine on day 1 was 5.89% +/- 1.4% of the dose in 24 h for the parent compound and 18.4% +/- 6.8% for the SPX glucuronide.,Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8203837/),%,5.89,262114,DB01208,Sparfloxacin
,8203837,Recovery in urine,Recovery in urine on day 1 was 5.89% +/- 1.4% of the dose in 24 h for the parent compound and 18.4% +/- 6.8% for the SPX glucuronide.,Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8203837/),%,18.4,262115,DB01208,Sparfloxacin
,10049262,total amount of unchanged,"The total amount of unchanged ciprofloxacin excreted over 24 h under acidic conditions was 88.4 +/- 14.5 mg (mean +/- standard deviation) (44.2% of the oral dose) and 82.4 +/- 16.5 mg (41.2% of the oral dose) under alkaline conditions, while the total amount of unchanged drug excreted over 24 h in volunteers receiving neither sodium bicarbonate nor ammonium chloride was 90.53 +/- 9.8 mg (45.2% of the oral dose).",Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049262/),mg,88.4,263349,DB01208,Sparfloxacin
,10049262,total amount of unchanged,"The total amount of unchanged ciprofloxacin excreted over 24 h under acidic conditions was 88.4 +/- 14.5 mg (mean +/- standard deviation) (44.2% of the oral dose) and 82.4 +/- 16.5 mg (41.2% of the oral dose) under alkaline conditions, while the total amount of unchanged drug excreted over 24 h in volunteers receiving neither sodium bicarbonate nor ammonium chloride was 90.53 +/- 9.8 mg (45.2% of the oral dose).",Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049262/),mg,82.4,263350,DB01208,Sparfloxacin
,10049262,total amount of unchanged drug excreted,"The total amount of unchanged ciprofloxacin excreted over 24 h under acidic conditions was 88.4 +/- 14.5 mg (mean +/- standard deviation) (44.2% of the oral dose) and 82.4 +/- 16.5 mg (41.2% of the oral dose) under alkaline conditions, while the total amount of unchanged drug excreted over 24 h in volunteers receiving neither sodium bicarbonate nor ammonium chloride was 90.53 +/- 9.8 mg (45.2% of the oral dose).",Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049262/),mg,90.53,263351,DB01208,Sparfloxacin
,10049262,renal clearance,"The mean renal clearance of ciprofloxacin was 16.78 +/- 2.67, 16.08 +/- 3.2, and 16.31 +/- 2.67 liters/h with acidification, alkalinization, and control, respectively.",Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049262/),[l] / [h],16.78,263352,DB01208,Sparfloxacin
,10049262,renal clearance,"The mean renal clearance of ciprofloxacin was 16.78 +/- 2.67, 16.08 +/- 3.2, and 16.31 +/- 2.67 liters/h with acidification, alkalinization, and control, respectively.",Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049262/),[l] / [h],16.08,263353,DB01208,Sparfloxacin
,10049262,renal clearance,"The mean renal clearance of ciprofloxacin was 16.78 +/- 2.67, 16.08 +/- 3.2, and 16.31 +/- 2.67 liters/h with acidification, alkalinization, and control, respectively.",Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049262/),[l] / [h],16.31,263354,DB01208,Sparfloxacin
,17145798,MICs,"MICs for Mycobacterium tuberculosis H37Rv were 0.1 mg/liter (sparfloxacin [SPX]) and 0.5 mg/liter (moxifloxacin [MXF], ciprofloxacin [CIP], and ofloxacin [OFX]).","Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145798/),[mg] / [l],0.1,263778,DB01208,Sparfloxacin
,17145798,MICs,"MICs for Mycobacterium tuberculosis H37Rv were 0.1 mg/liter (sparfloxacin [SPX]) and 0.5 mg/liter (moxifloxacin [MXF], ciprofloxacin [CIP], and ofloxacin [OFX]).","Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145798/),[mg] / [l],0.5,263779,DB01208,Sparfloxacin
,9860151,relative bioavailability,"The relative bioavailability of sparfloxacin was 84.4% and 122.3% after ammonium chloride and sodium bicarbonate treatments, respectively.",Sparfloxacin pharmacokinetics in healthy volunteers: the influence of acidification and alkalinization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860151/),%,84.4,273769,DB01208,Sparfloxacin
,9860151,relative bioavailability,"The relative bioavailability of sparfloxacin was 84.4% and 122.3% after ammonium chloride and sodium bicarbonate treatments, respectively.",Sparfloxacin pharmacokinetics in healthy volunteers: the influence of acidification and alkalinization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860151/),%,122.3,273770,DB01208,Sparfloxacin
